Journal Home
Search for

Volume 53, Issue 3, Pages 522-535 (March 2009)


View previous. 21 of 46 View next.

Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the Centers for Disease Control and Prevention

Andrew S. Levey, MD1Corresponding Author Informationemail address, Anton C. Schoolwerth, MD, MSHA2, Nilka Ríos Burrows, MPH, MT34, Desmond E. Williams, MD, PhD4, Karma Rabon Stith, PhD, CHES5, William McClellan, MD, MPH6

Received 8 September 2008; accepted 24 November 2008.

Chronic kidney disease (CKD) is a public health threat in the United States, with increasing prevalence, high costs, and poor outcomes. More widespread effort at the prevention, early detection, evaluation, and management of CKD and antecedent conditions could prevent complications of decreased kidney function, slow the progression of kidney disease to kidney failure, and reduce cardiovascular disease risk. In 2006, the Centers for Disease Control and Prevention (CDC) launched an initiative on CKD. As part of this initiative, the CDC convened an expert panel to outline recommendations for a comprehensive public health strategy to prevent the development, progression, and complications of CKD in the United States. The panel adapted strategies for primary, secondary, and tertiary prevention for chronic diseases to the conceptual model for the development, progression, and complications of CKD; reviewed epidemiological data from US federal agencies; and discussed ways of integrating public health efforts from various agencies and organizations. The panel recommended a 10-point plan to the CDC to improve surveillance, screening, education, and awareness directed at 3 target populations: people with CKD or at increased risk of developing CKD; providers, hospitals, and clinical laboratories; and the general public. Cooperation among federal, state, and local governmental and private organizations will be necessary to carry out these recommendations.

1 Division of Nephrology, Tufts Medical Center, Boston, MA

2 Dartmouth-Hitchcock Medical Center, Hanover, NH

3 Division of Diabetes Translation, Centers for Disease Control and Prevention

4 Centers for Disease Control and Prevention

5 Danya Int, Inc

6 Rollins School of Public Health, Emory University, Atlanta, GA

Corresponding Author InformationAddress correspondence to Andrew S. Levey, MD, Division of Nephrology, Tufts Medical Center, 800 Washington St, Box 391, Boston, MA 02111

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Michael Shlipak, MD, University of California, San Francisco) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(08)01730-7

doi:10.1053/j.ajkd.2008.11.019


View previous. 21 of 46 View next.